Pharmacological Evaluation of LiuWei Zhuanggu Granules in Rats
Abstract
:1. Introduction
2. Results and Discussion
Group | Uterine wet weight (mg) |
---|---|
NC | 1048.3 ± 132.5 |
Sham | 1072.1 ± 89.5 |
OVX | 205.3 ± 14.6 d |
OVX + LWZGG (1 g/kg b.w.) | 369.1 ± 27.7 f |
OVX + LWZGG (2.5 g/kg b.w.) | 482.5 ± 31.5 f |
Group | Estrogen (ng/L) | BGP (μg/L) | PTH (ng/L) | CT (μg/L) |
---|---|---|---|---|
NC | 4.71 ± 0.29 | 3.97 ± 0.28 | 2.08 ± 0.21 | 521.53 ± 46.27 |
Sham | 4.63 ± 0.37 | 4.05 ± 0.35 a | 1.98 ± 0.16 | 541.08 ± 38.91 |
OVX | 2.91 ± 0.22 d | 1.62 ± 0.73 d | 6.89 ± 0.53 d | 257.57 ± 32.38 d |
OVX+LWZGG (1 g/kg b.w.) | 3.78 ± 0.29 e | 2.28 ± 0.56 f | 4.81 ± 0.43 f | 402.48 ± 40.81 e |
OVX+LWZGG (2.5 g/kg b.w.) | 4.83 ± 0.34 f | 3.37 ± 0.31 f | 2.94 ± 0.22 f | 514.8 ± 44.05 f |
Group | Ca | Zn | Cu | ||||||
---|---|---|---|---|---|---|---|---|---|
Serum (mmol/L) | Bone (mg/g) | Urine (mg/g) | Serum (μmol/L) | Bone (μg/g) | Urine (μg/g) | Serum (μmol/L) | Bone (μg/g) | Urine (μg/g) | |
NC | 2.29 ± 0.15 | 306.71 ± 24.63 | 1.572 ± 0.131 | 13.61 ± 1.09 | 161.29 ± 12.35 | 2.516 ± 0.21 | 20.41 ± 1.48 | 6.04 ± 0.53 | 0.225 ± 0.016 |
Sham | 2.32 ± 0.18 | 298.64 ± 20.07 | 1.603 ± 0.132 | 12.99 ± 0.97 | 158.38 ± 11.37 | 2.603 ± 0.132 | 21.83 ± 1.08 | 5.99 ± 0.47 | 0.231 ± 0.013 |
OVX | 3.06 ± 0.23 | 236.17 ± 18.59 | 2.135 ± 0.165 | 18.82 ± 0.89 | 113.25 ± 9.54 | 3.361 ± 0.247 | 29.77 ± 1.85 | 4.61 ± 0.41 | 0.295 ± 0.021 |
OVX+LWZGG (1 g/kg b.w.) | 2.78 ± 0.17 | 268.14 ± 21.74 | 1.893 ± 0.111 | 16.05 ± 1.04 | 136.19 ± 8.46 | 3.063 ± 0.224 | 25.72 ± 2.07 | 5.45 ± 0.45 | 0.264 ± 0.019 |
OVX+LWZGG (2.5 g/kg b.w.) | 2.41 ± 0.19 | 299.21 ± 20.53 | 1.672 ± 0.132 | 14.07 ± 0.95 | 159.04 ± 11.43 | 2.639 ± 0.198 | 22.17 ± 1.64 | 5.85 ± 0.48 | 0.241 ± 0.016 |
Group | Femur density (g/cm2) | Lumbar vertebrae density (g/cm2) | Trabecular bone density (mm2 %) |
---|---|---|---|
NC | 0.3937 ± 0.0276 | 0.3927 ± 0.0333 | 0.9143 ± 0.0572 |
Sham | 0.3617 ± 0.0283 a | 0.4181 ± 0.0318 | 0.9188 ± 0.0739 |
OVX | 0.3052 ± 0.0291 d | 0.3164 ± 0.0274 d | 0.6936 ± 0.0516 d |
OVX+LWZGG (1 g/kg b.w.) | 0.3241 ± 0.0216 e | 0.3719 ± 0.0233 f | 0.8159 ± 0.0477 f |
OVX+LWZGG (2.5 g/kg b.w.) | 0.3379 ± 0.0325 f | 0.3946 ± 0.0317 f | 0.9052 ± 0.0691 f |
Group | Tibia maximum stress (MPa) | Tibia maximum bending strength (MPa) |
---|---|---|
NC | 275.6 ± 20.1 | 321.7 ± 30.5 |
Sham | 271.5 ± 23.6 | 318.6 ± 28.9 |
OVX | 218.9 ± 18.5 d | 268.3 ± 20.4 d |
OVX+BSZGG (1 g/kg b.w.) | 251.4 ± 20.9 f | 293.5 ± 22.2 f |
OVX+BSZGG (2.5 g/kg b.w.) | 268.3 ± 23.4 f | 311.5 ± 28.5 f |
3. Eperimental
3.1. Material
3.2. Animals and Treatments
3.3. Biochemical Assay
3.4. BMD Analysis
3.5. Biomechanical Testing Procedure
3.6. Statistical Analysis
4. Conclusions
- Sample Availability: Samples of LWZGG are available from the authors.
References
- Garnero, P.; Delmas, P.D. Osteoporosis. Endocrinol. Metab. Clin. N. Am. 1997, 26, 913–936. [Google Scholar] [CrossRef]
- Hans, D.; Fuerst, T.; Lang, T.; Majumdar, S.; Lu, Y.; Genant, H.K.; Glüer, C. How can we measure bone quality? Baillieres Clin. Rheumatol. 1997, 11, 495–515. [Google Scholar] [CrossRef]
- Stevenson, J.C. Justification for the use of HRT in the long-term prevention of osteoporosis. Maturitas 2005, 51, 113–126. [Google Scholar] [CrossRef]
- Prelevic, G.M.; Kocjan, T.; Markou, A. Hormone replacement therapy in postmenopausal women. Minerva Endocrinol. 2005, 30, 27–36. [Google Scholar]
- Eriksen, E.F. Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocr. Rev. 1986, 7, 379–408. [Google Scholar]
- Lerner, U.H. Bone remodeling in post-menopausal osteoporosis. J. Dent. Res. 2006, 85, 584–595. [Google Scholar] [CrossRef]
- Rubin, C.; Judex, S.; Qin, Y.X. Low-level mechanical signals and their potential as a non-pharmacological intervention for osteoporosis. Age Ageing 2006, 35, 32–36. [Google Scholar]
- Rubin, C.; Turner, A.S.; Bain, S.; Mallinckrodt, C.; McLeod, K. Anabolism. Low mechanical signals strengthen long bones. Nature 2001, 412, 603–604. [Google Scholar]
- Nancy, B. Phyto-oestrogens and compounds that affect oestrogen metabolism. Aust. J. Med. Herbalism 1995, 7, 11–16. [Google Scholar]
- Kühnau, J. The flavonoids. A class of semi-essential food components: Their role in human nutrition. World Rev. Nutr. Diet. 1976, 24, 117–191. [Google Scholar]
- Setchell, K.D. Phytoestrogens: The biochemistry, physiology, and implications for human health of soy isoflavones. Am. J. Clin. Nutr. 1998, 68, 1333–1346. [Google Scholar]
- Omi, N.; Ezawa, I. The effect of ovariectomy on bone metabolism in rats. Bone 1995, 17, 163–168. [Google Scholar]
- Bonjour, J.P.; Amman, P.; Rizzoli, R. Importance of preclinical studies in the development of drugs for treatment of osteoporosis: A review related to the 1998 WHO guidelines. Osteoporos Int. 1999, 9, 379–393. [Google Scholar] [CrossRef]
- Huang, R.Y.; Miller, L.M.; Carlson, C.S.; Chance, M.R. Characterization of bone mineral composition in the proximal tibia of Cynomolgus monkeys: Effect of ovariectomy and nandrolone decanoate treatment. Bone 2002, 30, 492–497. [Google Scholar] [CrossRef]
- Tobias, J.H.; Compston, J.E. Does estrogen stimulate osteoblast function in postmenopausal women? Bone 1999, 24, 121–124. [Google Scholar] [CrossRef]
- Dai, C.L.; Chen, L.; Qiu, M.C.; Wang, D.X.; Lu, B. The effects of osteogenic growth peptide C-terminal pentapeptide analogues on variectomized (OVX) rats. Bone 2008, 43, 47–48. [Google Scholar]
- Kafantari, H.; Kounadi, E.; Fatouros, M.; Milonakis, M.; Tzaphlidou, M. Structural alterations in rat skin and bone collagen fibrils induced by ovariectomy. Bone 2000, 26, 349–353. [Google Scholar]
- Dempster, D.W.; Cosman, F.; Parisien, M.; Shen, V.; Lindsay, R. Anabolic actions of parathyroid hormone on bone. Endocr. Rev. 1993, 14, 690–709. [Google Scholar]
- Lindsay, R.; Nieves, J.; Formica, C.; Henneman, E.; Woelfert, L.; Shen, V.; Dempster, D.; Cosman, F. Randomized controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997, 350, 550–555. [Google Scholar]
- Morley, R.; Whitfield, J.F.; Willick, G.E. Anabolic effects of parathyroid hormone on bone. Trends Endocrinol. Metab. 1997, 8, 225–231. [Google Scholar]
- Reeve, J. PTH: A future role in the management of osteoporosis? J. Bone Miner Res. 1996, 11, 440–445. [Google Scholar] [CrossRef]
- Whitfield, J.F.; Morley, P. Anabolic Treatments for Osteoporosis; CRC Press: Boca Raton, FL, USA, 1998. [Google Scholar]
- Dobnig, H.; Turner, R. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997, 138, 4607–4612. [Google Scholar] [CrossRef]
- Alkahtani, S.; AL-Farraj, S.A.; Alarifi, S.A.; Saad, A.E.M.; Al-Dahmash, B. Cytokine genes expression in mice hepatocytes during malaria infection. Afr. J. Microbiol. Res. 2011, 5, 2311–2315. [Google Scholar]
- Gruber, H.E.; Grigsby, J.; Chesnut, C.H., III. Osteoblast numbers after calcitonin therapy: A retrospective study of paired biopsies obtained during long-term calcitonin therapy in postmenopausal osteoporosis. Calcif. Tissue Int. 2000, 66, 29–34. [Google Scholar] [CrossRef]
- Kim, T.-H.; Jung, J.W.; Ha, B.G.; Hong, J.M.; Park, E.K.; Kim, H.J.; Kim, S.Y. The effects of luteolin on osteoclast differentiation, function in vitro and ovariectomy-induced bone loss. J. Nutr. Biochem. 2011, 22, 8–15. [Google Scholar] [CrossRef]
- Obameso, J.O.; Akinyele, B.J.; Oladunmoye, M.K.; Osho, I.B. Immunomodulatory and toxicological properties of some selected Ganoderma mushrooms species. Afr. J. Microbiol. Res. 2011, 5, 4622–4626. [Google Scholar]
- Rico, H.; Gómez-Raso, N.; Revilla, M.; Hernández, E.R.; Seco, C.; Páez, E.; Crespo, E. Effects on bone loss of manganese alone or with copper supplement in ovariectomized rats: A morphometric and densitomeric study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2000, 90, 97–101. [Google Scholar] [CrossRef]
- Lecanda, F.; Warlow, P.M.; Halstead, L.R.; Steinberg, T.H.; Civitelli, R. Impaired intramembranous bone formation in connexin43 null mice. Bone 1998, 23, 149–153. [Google Scholar] [CrossRef]
- Ward, W.E.; Kim, S.; Chan, D.; Fonseca, D. Serum equol, bone mineral density and biomechanical bone strength differ among four mouse strains. J. Nutr. Biochem. 2005, 16, 743–749. [Google Scholar]
- Rico, H.; Gómez-Raso, N.; Revilla, M.; Hernández, E.R.; Seco, C.; Páez, E.; Crespo, E. Effects on bone loss of manganese alone or with copper supplement in ovariectomized rats: A morphometric and densitomeric study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2000, 90, 97–101. [Google Scholar]
- Jain, P.; Bhuiyan, M.H.; Hossain, K.R.; Bachar, S.C. Antibacterial and antioxidant activities of local seeded banana fruits. Afr. J. Pharm. Pharmacol. 2011, 5, 1398–1403. [Google Scholar]
- Pinto, J.P.; Ohresser, M.C.P.; Cancela, M.L. Cloning of the bone Gla protein gene from the teleost fish Sparus aurata. Evidence for overall conservation in gene organization and bone-specific expression from fish to man. Gene 2001, 270, 77–91. [Google Scholar]
- Hilliker, S.; Wergedal, J.E.; Gruber, H.E.; Bettica, P.; Baylink, D.J. Truncation of the amino terminus of PTH alters its anabolic activity on bone in vivo. Bone 1996, 19, 469–477. [Google Scholar]
- Zaręba, S.; Szarwiło, K.; Pomykalski, A. Determination of Fe(II) and Zn(II) by spectrophotometry, atomic absorption spectrometry and ions chromatography methods in Vitrum. Il Farmaco 2005, 60, 459–464. [Google Scholar] [CrossRef]
- Pastoureau, P.; Chomel, A.; Bonnet, J. Specific evaluation of localized bone mass and bone loss in the rat using dual-energy X-ray absorptiometry subregional analysis. Osteoporos Int. 1995, 5, 143–149. [Google Scholar] [CrossRef]
- Shen, Y.; Li, Y.Q.; Li, S.P.; Ma, L.; Ding, L.J.; Ji, H. Alleviation of ovariectomyinduced osteoporosis in rats by Panax notoginseng saponins. J. Nat. Med. 2010, 64, 336–345. [Google Scholar]
© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Zhu, H.; Ding, L.; Xiao, H.; Ni, W.; Xue, F.; He, Z. Pharmacological Evaluation of LiuWei Zhuanggu Granules in Rats. Molecules 2012, 17, 8001-8009. https://doi.org/10.3390/molecules17078001
Zhu H, Ding L, Xiao H, Ni W, Xue F, He Z. Pharmacological Evaluation of LiuWei Zhuanggu Granules in Rats. Molecules. 2012; 17(7):8001-8009. https://doi.org/10.3390/molecules17078001
Chicago/Turabian StyleZhu, Haiming, Liang Ding, Haijun Xiao, Weifeng Ni, Feng Xue, and Zhiming He. 2012. "Pharmacological Evaluation of LiuWei Zhuanggu Granules in Rats" Molecules 17, no. 7: 8001-8009. https://doi.org/10.3390/molecules17078001